IN THE NEWS

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

May 9th, 2019|

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update First-Ever Phase 3 HDV International “D-LIVR” Study UnderwayNDA and MAA filings for Progeria & Progeroid Laminopathies planned in 2019Strong Balance Sheet with Recent Financing CompletedPALO ALTO, Calif., May 9, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for the three months ended March 31, 2019 and provided a business update.“Eiger is [...]

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 2019

April 30th, 2019|

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 2019 PALO ALTO, Calif., April 30, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will participate and present a corporate update at the ChinaBio® Partnering Forum 2019 on May 8th in Shanghai, China. Eiger will host one-on-one meetings at the ChinaBio® Partnering Forum. About Eiger Eiger is a late stage [...]

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock – 4/17/2019

April 17th, 2019|

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock - 4/17/2019 Palo Alto, Calif., April 17, 2019, Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share. All of the shares are being sold by Eiger. The gross proceeds to Eiger from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be [...]